Metvid 50/500mg Tablet

Metvid 50/500mg Tablet is a combination medication that contains two active ingredients: Vildagliptin & Metformin. It is formulated as an oral tablet for the management of type 2 diabetes mellitus.

Active Ingredients:

1. Vildagliptin: This medication belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by inhibiting the enzyme DPP-4, which leads to increased levels of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones stimulate insulin secretion and inhibit glucagon release, resulting in improved blood glucose control.
2. Metformin: Metformin is a biguanide antidiabetic agent that works primarily by reducing hepatic glucose production and increasing insulin sensitivity in peripheral tissues. It also improves glucose uptake and utilization by skeletal muscle.

Uses:

Metvid 50/500mg Tablet is indicated for the treatment of type 2 diabetes mellitus in adults:

• It helps to improve glycemic control by lowering fasting and postprandial blood glucose levels.
• The combination of Vildagliptin and Metformin offers complementary mechanisms of action, resulting in improved efficacy compared to either drug alone.

Mechanism of Action:

Vildagliptin and Metformin work through different mechanisms to achieve blood glucose control:

• Vildagliptin increases insulin secretion and inhibits glucagon release by enhancing the effects of incretin hormones.
• Metformin reduces hepatic glucose production, enhances insulin sensitivity, and improves peripheral glucose uptake.

Administration:

Take Metvid 50/500mg Tablet orally, with meals, as directed by a healthcare professional. The dosage may vary depending on the patient’s glycemic control and renal function. It is essential to adhere to the prescribed regimen and follow up with regular monitoring of blood glucose levels.

Side Effects:

Common side effects of Metvid 50/500mg Tablet may include:

• Nausea or vomiting
• Diarrhea
• Abdominal discomfort
• Headache
• Hypoglycemia (low blood sugar) when used with other antidiabetic medications

Precautions:

• Patients with renal impairment should use Metvid with caution, as both Vildagliptin and Metformin are excreted primarily by the kidneys. Dose adjustments may be necessary based on renal function.
• Hypoglycemia may occur when Metvid is used in combination with other antidiabetic medications, particularly insulin or sulfonylureas. Close monitoring of blood glucose levels is recommended.

When Not to Use:

Metvid 50/500mg Tablet is contraindicated in patients with:

• Hypersensitivity to Vildagliptin, Metformin, or any components of the tablet.
• Severe renal impairment (eGFR less than 30 mL/min/1.73 m²) or end-stage renal disease.
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis.